Target to test same-day delivery in select markets
MINNEAPOLIS — The online shipping war among retailers continues to heat up as Target plans to launch a same-day delivery pilot in June in select markets.
Target will launch a $10 rush delivery pilot in June in the Minneapolis, Boston and Miami markets, offering guests the ability to order as late as 1:30 p.m. in the afternoon and receive a delivery of qualifying items between 6 p.m. and 9 p.m. the same day, the company stated in its recent quarterly call with analysts.
Later in the year, Target plans to rollout standard shipping from 136 stores in 38 markets across the country. By leveraging the store network as fulfillment centers, it can offer faster, standard shipping — typically one to two days — and provide access to store only items not previously available from Target.com. The retailer stated that it will continue to monitor results to determine further rollout plans.
The retailer also stated that it continues to see “encouraging results” from its recent rollout of in-store pickup of digital orders. These orders make up about 10% of Target’s digital transactions and when guests pick up their items, more than 20% of the time, they take the opportunity to shop the store and spend much more than the average basket, the company stated. In the first quarter, Target expanded the number of SKUs eligible for in-store pickup to more than 60,000, including some shelf stable grocery items.
Dalvance receives FDA approval
SILVER SPRING, Md. — The Food and Drug Administration on Friday approved Dalvance (dalbavancin), a new antibacterial drug used to treat adults with acute bacterial skin and skin structure infections, such as staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains) and streptococcus pyogenes.
Dalvance is the first drug to be designated as a qualified infection disease product to receive the agency’s approval. It was granted QIDP status because it is an antibacterial or antifungal human drug intended to treat serious or life-threatening infections, according to the FDA.
Dalvance, which is adminstered intravenously, was granted priority review. The drug’s QIDP designation qualifies it for an additional five years of marketing exclusivity. Dalvance is marketed by Durata Therapeutics, which is based in Chicago.